Table 1.
Drugs targeting Wnt pathways. All depicted drugs are currently undergoing phase1/2 clinical trials against various types of cancers.
| Target gene | Compound | Cancer |
|---|---|---|
| Wnt-5a | Foxy5 | BCa, CRC, PCa |
| Porcupine | LGK974, ETC-159 | Metastatic CRC, HNSCC, other solid tumors |
| PTK7 | PF-06647020 | Advanced solid tumors |
| R-Spondin 3 | OMP131R10 | Metastatic CRC |
| FRIZZLED-10 | SYNFRIZZ, OTSA101 | Advanced synovial sarcoma |
| FRIZZLED-7 | OMPI8R5 (vantictumab) | NSCLC, metastatic BCa, PDAC |
| FIRZZLED-8 | OMP54F28 | Ovarian cancer, PDAC, HCC |
| TCF/β-catenin interaction | PRI-724 | AML, CML, CRC, PDAC |
AML: acute myeloid leukemia; BCa: breast cancer; CML: chronic myelogenous leukemia; CRC: colorectal cancer; HCC: hepatocellular carcinoma; HNSCC: head and neck squamous cell carcinoma; NSCLC: non-small-cell lung carcinoma; PCa: prostate cancer; PDAC: pancreatic ductal adenocarcinoma.